Inactive Instrument

Biotech Acquisition Company

BIOT

KYG1125A1085

Biotech Acquisition Company Announces Resignation of Michael Tillman as an Advisor

March 17, 2021 at 06:04 am

Biotech Acquisition Company announced that, as of the date hereof, Mr. Michael Tillman has ceased to serve as an advisor to the Company.

Latest news about Biotech Acquisition Company

Biotech Acquisition to Dissolve, Liquidate	23-02-02	MT
Biotech Acquisition Company(NasdaqCM:BIOT) dropped from NASDAQ Composite Index	23-02-02	CI
Biotech Acquisition Says New Sponsor to Make Additional Contributions Related to Proposed Business Combination Extension	23-01-05	MT
Biotech Acquisition Company Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-22	CI
Biotech Acquisition Company announced that it expects to receive $0.25 million in funding	22-10-03	CI
Biotech Acquisition, Blade Therapeutics Agree to Terminate Merger Agreement	22-06-13	MT
Biotech Acquisition Company cancelled the transaction announced on November 8, 2021	22-06-09	CI
Blade Therapeutics, Inc. cancelled the acquisition of Biotech Acquisition Company from Biotech Sponsor LLC and others in a reverse merger transaction.	22-06-09	CI
Biotech Acquisition Postpones Extraordinary Meeting of Shareholders to Approve Proposed Merger With Blade Therapeutics	22-06-03	MT
Biotech Acquisition Company Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-16	CI
Blade Therapeutics Gets FDA Feedback Letter for Cudetaxestat	22-04-04	DJ
Biotech Acquisition Company Auditor Raises 'Going Concern' Doubt	22-03-07	CI
Blade Therapeutics Says Treatment for Lung Scarring Condition Was Well Tolerated in Phase 1 Study	22-01-12	MT
Blank Check Firm Biotech Acquisition to Merge With Blade Therapeutics	21-11-08	MT
Biotech Acquisition Company announced that it expects to receive $24.3 million in funding from Bristol-Myers Squibb Company, Deerfield Management Company, L.P., Pfizer Venture Investments LLC, Osage University Partners, MPM Asset Management, L.L.C. and other investors	21-11-07	CI
Blade Therapeutics, Inc. entered into a definitive Agreement and Plan of Merger to acquire Biotech Acquisition Company from Biotech Sponsor LLC and others in a reverse merger transaction.	21-11-07	CI
Certain Class B Ordinary Shares of Biotech Acquisition Company are subject to a Lock-Up Agreement Ending on 25-JUL-2021.	21-07-24	CI
Biotech Acquisition Company(NasdaqCM:BIOT) added to NASDAQ Composite Index	21-03-23	CI
Biotech Acquisition Company Announces Resignation of Michael Tillman as an Advisor	21-03-17	CI
Biotech Acquisition Company announced that it has received $6 million in funding from Biotech Sponsor LLC	21-01-27	CI
Biotech Acquisition Company has completed an IPO in the amount of $200 million.	21-01-25	CI
Biotech Acquisition Company has filed an IPO in the amount of $200 million.	20-12-30	CI
Biotech Acquisition Company announced that it expects to receive $6 million in funding from Biotech Sponsor LLC	20-12-29	CI

Chart Biotech Acquisition Company

Duration

Period

More charts

Biotech Acquisition Company is a blank check company. The Company is created for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or other similar business combination with one or more businesses. The Company focuses for a target business in the healthcare sector. It has no operations and has no revenues.

Sector

Investment Holding Companies

More about the company

Sector Shell Companies

	1st Jan change	Capi.
TRUMP MEDIA & TECHNOLOGY GROUP CORP.	+169.83%	8.67B
CHURCHILL CAPITAL CORP VII	+2.29%	983M
APPLE ISPORTS GROUP, INC.	+41.91%	883M
PERELLA WEINBERG PARTNERS	+23.96%	825M
ARES ACQUISITION CORPORATION II	+1.96%	665M
E7 GROUP	+7.72%	664M
DA ZHONG TRADING GROUP HOLDING COMPANY	-.--%	600M
ADMIRAL ACQUISITION LIMITED	+8.06%	530M
CAPITOL INVESTMENT CORP. VII	-.--%	500M

Shell Companies